AbsEn.i
Analysis
2020
Racine
Analysis
2020
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « bdmards »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
bdmard < bdmards < bead  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 15.
Ident.Authors (with country if any)Title
000082 (2020) Eun-Jung Park [Corée du Sud] ; Hyungjin Kim [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Yoon-Kyoung Sung [Corée du Sud] ; Han Joo Baek [Corée du Sud] ; Jisoo Lee [Corée du Sud]The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
000109 (2020) Eric Toussirot [France]The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition
000139 (2020) Chayma Ladhari [France] ; Pierre Le Blay [France] ; Thierry Vincent [France] ; Ahmed Larbi [France] ; Emma Rubenstein [France] ; Rosanna Ferreira Lopez [France] ; Christian Jorgensen [France] ; Yves-Marie Pers [France]Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study
000151 (2020) Joanna Wai Yee Leong [Singapour] ; Peter P. Cheung [Singapour] ; Sajeewani Dissanayake [Singapour] ; Warren Weng Seng Fong [Singapour] ; Keng Hong Leong [Singapour] ; Ying Ying Leung [Singapour] ; Anita Yee Nah Lim [Singapour] ; Nai Lee Lui [Singapour] ; Mona Manghani [Singapour] ; Amelia Santosa [Singapour] ; Melonie Kannamma Sriranganathan [Singapour] ; Ernest Suresh [Singapour] ; Teck Choon Tan [Singapour] ; Gim Gee Teng [Singapour] ; Manjari Lahiri [Singapour]Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
000169 (2020) Maria Antonietta Barbieri [Italie] ; Giuseppe Cicala [Italie] ; Paola Maria Cutroneo [Italie] ; Elisabetta Gerratana [Italie] ; Caterina Palleria [Italie] ; Caterina De Sarro [Italie] ; Ada Vero [Italie] ; Luigi Iannone [Italie] ; Antonia Manti [Italie] ; Emilio Russo [Italie] ; Giovambattista De Sarro [Italie] ; Fabiola Atzeni [Italie] ; Edoardo Spina [Italie]Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study.
000204 (2020) Jennie H. Best [États-Unis] ; Steven C. Vlad [États-Unis] ; Lenore Tominna [États-Unis] ; Ibrahim Abbass [États-Unis]Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic.
000218 (2020) Piero Ruscitti [Italie] ; Paola Cipriani [Italie] ; Vasiliki Liakouli [Italie] ; Daniela Iacono [Italie] ; Ilenia Pantano [Italie] ; Francesco Caso [Italie] ; Federico Perosa [Italie] ; Fabiola Atzeni [Italie] ; Francesco Paolo Cantatore [Italie] ; Raffaele Scarpa [Italie] ; Francesco Ciccia [Italie] ; Roberto Giacomelli [Italie]Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
000324 (2020) Sae Ochi [Japon] ; Kazuyoshi Saito [Japon] ; Fumitaka Mizoguchi [Japon] ; Shigeaki Kato [Japon] ; Yoshiya Tanaka [Japon]Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
000363 (2020) Elisa Gremese [Italie] ; Antonio Gasbarrini [Italie] ; Gianfranco Ferraccioli [Italie]HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
000424 (2020) Salah Ghabri [France] ; Aymeric Binard [France] ; Yves-Marie Pers [France] ; Franck Maunoury [France] ; J Jaime Caro [États-Unis]Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France.
000432 (2020) Kosuke Ebina [Japon] ; Toru Hirano [Japon] ; Yuichi Maeda [Japon] ; Wataru Yamamoto [Japon] ; Motomu Hashimoto [Japon] ; Koichi Murata [Japon] ; Tohru Takeuchi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Akira Onishi [Japon] ; Sadao Jinno [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Keiichi Yamamoto [Japon] ; Atsushi Kumanogoh [Japon] ; Makoto Hirao [Japon]Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
000433 (2020) Corrado Campochiaro [Italie] ; Alessandro Tomelleri [Italie] ; Silvia Sartorelli [Italie] ; Giulio Cavalli [Italie] ; Giacomo De Luca [Italie] ; Elena Baldissera [Italie] ; Lorenzo Dagna [Italie]Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis.
000459 (2020) Benjamin Birkner [Allemagne] ; Jürgen Rech [Allemagne] ; Tom Stargardt [Allemagne]Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
000485 (2020) Kim Lauper [Suisse] ; Denis Mongin [Suisse] ; Florenzo Iannone [Italie] ; Eirik K. Kristianslund [Norvège] ; Tore K. Kvien [Norvège] ; Dan C. Nordström [Finlande] ; Karel Pavelka [République tchèque] ; Manuel Pombo-Suarez [Espagne] ; Ziga Rotar [Slovénie] ; Maria J. Santos [Portugal] ; Catalin Codreanu [Roumanie] ; Galina Lukina [Russie] ; Sara L. Gale [États-Unis] ; Markus John [Suisse] ; Yves Luder [Suisse] ; Delphine S. Courvoisier [Suisse] ; Cem Gabay [Suisse]Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
000571 (2020) Seong-Kyu Kim ; Sang Gyu Kwak [Corée du Sud] ; Jung-Yoon ChoeAssociation between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: Results from prospective nationwide KOBIO Registry.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "bdmards" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "bdmards" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    bdmards
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021